<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821236</url>
  </required_header>
  <id_info>
    <org_study_id>WLCVLV-001</org_study_id>
    <nct_id>NCT00821236</nct_id>
  </id_info>
  <brief_title>Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK</brief_title>
  <acronym>WLCVLV-001</acronym>
  <official_title>A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Wave™ Excimer Laser in One Eye and the Amo/Visx Customvue™ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durrie Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durrie Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare LASIK outcomes using the WaveLight ALLEGRETTO WAVE™
      wavefront guided or optimized excimer laser treatment with the AMO/VISX CustomVue™ and the
      LADARVision 4000 excimer laser treatment.

      Standard refractive outcomes such as uncorrected and best corrected visual acuity, and
      intended vs. achieved postoperative refractions will be evaluated; in addition, high order
      optical aberrations, contrast sensitivity, and topography will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare WaveLight ALLEGRETTO WAVE™ wavefront guided
      or optimized excimer laser treatment with the AMO/VISX CustomVue™ and the LADARVision 4000
      excimer laser treatment using both subjective and objective outcome measures. This comparison
      will be made between fellow eyes of the same patient following excimer laser ablation using
      the WaveLight ALLEGRETTO WAVE™ Excimer Laser System in one eye and the AMO/VISX CustomVue™ or
      the LADARVision 4000 excimer laser in the contralateral eye .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 Day Postoperative Lasik Uncorrected Visual Acuity</measure>
    <time_frame>1 Day</time_frame>
    <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1 Week Postoperative Lasik Uncorrected Visual Acuity</measure>
    <time_frame>1 week post op</time_frame>
    <description>Visual acuity measured withouth glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1 Month Postoperative Lasik Visual Acuity</measure>
    <time_frame>1 Month Postoperative</time_frame>
    <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Wavelight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMO/VISX CustomVue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMO/VISX CustomVue™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LADARVision 4000 excimer laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LADARVision 4000 excimer laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer Laser</intervention_name>
    <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
    <arm_group_label>Wavelight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMO/VISX CustomVue™</intervention_name>
    <description>Excimer Laser</description>
    <arm_group_label>AMO/VISX CustomVue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LADARVision 4000 excimer laser</intervention_name>
    <description>Excimer Laser</description>
    <arm_group_label>LADARVision 4000 excimer laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have up to -7.00D of spherical equivalent myopia or myopia with
             astigmatism, with up to -7.00D of spherical component and up to 3.00 D of astigmatic
             component at the spectacle plane in both eyes.

          -  Subjects must have a stable refraction as documented by previous clinical records.
             Spherical equivalent has not progressed at a rate of more than 0.50D per year prior to
             the baseline examination in both eyes or as documented by clinical judgment by the
             investigator.

          -  Subjects who wear contact lenses must discontinue wear at least 3 days for soft and at
             least 3 weeks for RGP prior to the preoperative evaluation or surgery, in either eye.

          -  Subjects must have visual acuity correctable to at least 20/20 in both eyes.

          -  Subjects must be at least 18 years of age.

          -  Subjects must be willing and able to return for scheduled follow up examinations for
             twelve months after LASIK surgery.

          -  Subjects must sign and be given a copy of the written Informed Consent form.

        Exclusion Criteria:

          -  Subjects for whom both eyes do not meet all inclusion criteria and either eye meets
             any exclusion criteria.

          -  Subjects for whom the combination of their baseline corneal thickness and the planned
             operative parameters for the LASIK procedure would result in less than 250 microns of
             remaining posterior corneal thickness below the flap postoperatively in either eye.

          -  Eyes for which the baseline standard manifest refraction exhibits greater than 1.00D
             more minus in sphere power, or a difference of greater than 0.75 D in cylinder power.

          -  Subjects desiring spherical under correction in one eye (i.e. no monovision correction
             is permitted).

          -  Subjects for whom the preoperative assessment of the ocular topography and /or
             aberrations indicates that either eye is not a suitable candidate for LASIK vision
             correction procedure. Examples include frank or forme frust keratoconus, corneal
             warpage, pellucid marginal degeneration, etc.

          -  Subjects with clinically significant dry eye syndrome or clinically significant
             blepharitis in either eye.

          -  Subjects with anterior segment pathology, including clinically significant cataracts
             or corneal scarring or neovascularization in either eye.

          -  Subjects with residual, recurrent, active ocular or eyelid disease, including any
             corneal abnormality (specifically, recurrent corneal erosion, severe basement membrane
             disease) in either eye.

          -  Subjects with ophthalmoscopic signs of progressive or unstable myopia or keratoconus
             (or keratoconus suspect) in either eye.

          -  Subjects with unstable (distorted/not clear) corneal mires on central keratometry in
             either eye.

          -  Subjects who have undergone previous intraocular or corneal surgery of any kind,
             including any type of surgery for either refractive or therapeutic purposes in either
             eye.

          -  Subjects who have a history of Herpes zoster or Herpes simplex keratitis.

          -  Subjects on chronic systemic corticosteroid or other immunosuppressive therapy that
             may affect wound healing, any immunocompromised subjects, and subjects with clinically
             significant atopic disease, connective tissue disease, or diabetes.

          -  Subjects with a history of steroid-responsive rise in intraocular pressure, glaucoma,
             or preoperative Intraocular pressure&gt;23 mm Hg in either eye.

          -  Subjects with macular pathology in either eye.

          -  Subjects who are pregnant, lactating, or planning to be pregnant during the course of
             the study.

          -  Subjects with known sensitivity to planned study concomitant medications.

          -  Subjects participating in any other ophthalmic drug or device clinical trial during
             the time of this clinical investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S. Durrie, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karl G. Stonecipher, MD</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <results_first_submitted>March 24, 2011</results_first_submitted>
  <results_first_submitted_qc>January 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2013</results_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Durrie Vision</investigator_affiliation>
    <investigator_full_name>Daniel S. Durrie, MD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Myopia</keyword>
  <keyword>LASIK</keyword>
  <keyword>Astigmatism</keyword>
  <keyword>Laser Vision Correction</keyword>
  <keyword>Excimer Laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lasik for Treatment of Nearsightedness</title>
          <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment LADARVision 4000 excimer laser AMO/VISX CustomVue™ excimer laser treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Wavelight</title>
          <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
        </group>
        <group group_id="B2">
          <title>AMO/VISX CustomVue</title>
          <description>AMO/VISX CustomVue™</description>
        </group>
        <group group_id="B3">
          <title>LADARVision 4000 Excimer Laser</title>
          <description>LADARVision 4000 excimer laser treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1 Day Postoperative Lasik Uncorrected Visual Acuity</title>
        <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
        <time_frame>1 Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wavelight</title>
            <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
          </group>
          <group group_id="O2">
            <title>AMO/VISX CustomVue</title>
            <description>AMO/VISX CustomVue™</description>
          </group>
          <group group_id="O3">
            <title>LADARVision 4000 Excimer Laser</title>
            <description>LADARVision 4000 excimer laser treatment</description>
          </group>
        </group_list>
        <measure>
          <title>1 Day Postoperative Lasik Uncorrected Visual Acuity</title>
          <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
          <units>LogMar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.08"/>
                    <measurement group_id="O2" value="-0.05" spread="0.06"/>
                    <measurement group_id="O3" value="0.06" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>1 Week Postoperative Lasik Uncorrected Visual Acuity</title>
        <description>Visual acuity measured withouth glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
        <time_frame>1 week post op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wavelight</title>
            <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
          </group>
          <group group_id="O2">
            <title>AMO/VISX CustomVue</title>
            <description>AMO/VISX CustomVue™</description>
          </group>
          <group group_id="O3">
            <title>LADARVision 4000 Excimer Laser</title>
            <description>LADARVision 4000 excimer laser treatment</description>
          </group>
        </group_list>
        <measure>
          <title>1 Week Postoperative Lasik Uncorrected Visual Acuity</title>
          <description>Visual acuity measured withouth glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
          <units>LogMar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="5.27"/>
                    <measurement group_id="O2" value="-0.09" spread="2.36"/>
                    <measurement group_id="O3" value="-0.02" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>1 Month Postoperative Lasik Visual Acuity</title>
        <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
        <time_frame>1 Month Postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Wavelight</title>
            <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
          </group>
          <group group_id="O2">
            <title>AMO/VISX CustomVue</title>
            <description>AMO/VISX CustomVue™</description>
          </group>
          <group group_id="O3">
            <title>LADARVision 4000 Excimer Laser</title>
            <description>LADARVision 4000 excimer laser treatment</description>
          </group>
        </group_list>
        <measure>
          <title>1 Month Postoperative Lasik Visual Acuity</title>
          <description>Visual acuity measured without glasses or contact lenses. LogMar is a method of measuring visual acuity. Generally speaking, the U.S. population is familiar with 20/20 visual acuity reference. Samples of LogMar equivalent values would be 20/20=0.0 LogMar, 20/25=0.1 LogMar, 20/16=-0.1, etc.</description>
          <units>LogMar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.09"/>
                    <measurement group_id="O2" value="-0.11" spread="0.06"/>
                    <measurement group_id="O3" value="0.08" spread="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Wavelight</title>
          <description>WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment</description>
        </group>
        <group group_id="E2">
          <title>AMO/VISX CustomVue</title>
          <description>AMO/VISX CustomVue™</description>
        </group>
        <group group_id="E3">
          <title>LADARVision 4000 Excimer Laser</title>
          <description>LADARVision 4000 excimer laser treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigette Ellis</name_or_title>
      <organization>Durrie Vision</organization>
      <phone>913-491-3330 ext 7255</phone>
      <email>bellis@durrievision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

